What type of study is this?

This is a Systematic Review study.

December 8, 2025BloodOpen Access

Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors

View Full Paper

Ask AI

Bookmark

Authors

Systematic review reports incidence of secondary malignancies in chronic myeloid leukemia treated with TKIs, suggesting a need for better monitoring.

Secondary malignancies emerged in 3.1% to 7.5% of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Highest incidences of gastrointestinal, genitourinary, and respiratory cancers were reported, stressing the importance of risk monitoring.
Systematic review analyzed 14 studies involving 42,781 chronic-phase CML patients, emphasizing the need for long-term safety evaluations.
Increased mortality and poor prognosis are linked to secondary malignancies, highlighting the need for further large-scale studies.

Benkhadra et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review reports incidence of secondary malignancies in chronic myeloid leukemia treated with TKIs, suggesting a need for better monitoring.

Secondary malignancies emerged in 3.1% to 7.5% of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Highest incidences of gastrointestinal, genitourinary, and respiratory cancers were reported, stressing the importance of risk monitoring.
Systematic review analyzed 14 studies involving 42,781 chronic-phase CML patients, emphasizing the need for long-term safety evaluations.
Increased mortality and poor prognosis are linked to secondary malignancies, highlighting the need for further large-scale studies.

Benkhadra et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark